TIGIT and cancer: Strong preclinical evidence supports blocking the TIGIT pathway for cancer immunotherapy12,19–22, although a recent Phase III clinical trial of anti-TIGIT tiragolumab combined with anti-PD-L1 (Tecentriq) failed.